{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T10:12:28Z","timestamp":1793873548702,"version":"4.6.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.annonc.2025.01.001","type":"journal-article","created":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T18:20:35Z","timestamp":1736619635000},"page":"583-591","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced\/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib"],"prefix":"10.1016","volume":"36","author":[{"given":"H.","family":"Horinouchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.C.","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.R.","family":"Camidge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Tomasini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Vasilopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Brunsdon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Bolotin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4429-512X","authenticated-orcid":false,"given":"V.","family":"Blot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2025.01.001_bib2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.5306\/wjco.v12.i4.217","article-title":"Oncogenic driver mutations in non-small cell lung cancer: past, present and future","volume":"12","author":"Chevallier","year":"2021","journal-title":"World J Clin Oncol"},{"key":"10.1016\/j.annonc.2025.01.001_bib3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s40291-021-00563-1","article-title":"Worldwide prevalence of epidermal growth factor receptor mutations in non-small cell lung cancer: a meta-analysis","volume":"26","author":"Melosky","year":"2022","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.annonc.2025.01.001_bib4","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2025.01.001_bib5","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.e20660","article-title":"C-MET overexpression as a resistance biomarker to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer","volume":"34","author":"Lee","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2025.01.001_bib6","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrc3205","article-title":"Targeting MET in cancer: rationale and progress","volume":"12","author":"Gherardi","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.annonc.2025.01.001_bib7","doi-asserted-by":"crossref","first-page":"4074","DOI":"10.1038\/s41467-021-24367-3","article-title":"Structural basis of the activation of c-MET receptor","volume":"12","author":"Uchikawa","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.annonc.2025.01.001_bib8","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12943-018-0796-y","article-title":"Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities","volume":"17","author":"Zhang","year":"2018","journal-title":"Mol Cancer"},{"key":"10.1016\/j.annonc.2025.01.001_bib9","doi-asserted-by":"crossref","first-page":"S1169","DOI":"10.1016\/j.jtho.2021.08.633","article-title":"P60.12 - Prevalence of c-Met overexpression (c-Met+) and impact of prior lines of treatment on c-Met protein expression in NSCLC","volume":"16","author":"Motwani","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.annonc.2025.01.001_bib10","doi-asserted-by":"crossref","first-page":"5781","DOI":"10.1158\/1078-0432.CCR-21-0765","article-title":"Phase I study of 2- or 3-week dosing of telisotuzumab vedotin, an antibody-drug conjugate targeting c-Met, monotherapy in patients with advanced non-small cell lung carcinoma","volume":"27","author":"Camidge","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2025.01.001_bib11","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1200\/JCO.2018.78.7697","article-title":"First-in-human phase I, dose-escalation and -expansion study of telisotuzumab vedotin, an antibody-drug conjugate targeting c-Met, in patients with advanced solid tumors","volume":"36","author":"Strickler","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"25","key":"10.1016\/j.annonc.2025.01.001_bib12","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/JCO.24.00720","article-title":"Telisotuzumab vedotin monotherapy in patients with previously treated c-Met protein\u2013overexpressing advanced nonsquamous EGFR-wildtype non-small cell lung cancer in the phase II LUMINOSITY trial","volume":"42","author":"Camidge","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2025.01.001_bib13","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1200\/JCO.22.00739","article-title":"Phase Ib study of telisotuzumab vedotin in combination with erlotinib in patients with c-Met protein-expressing non-small-cell lung cancer","volume":"41","author":"Camidge","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2025.01.001_bib14","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2025.01.001_bib15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2025.01.001_bib16","doi-asserted-by":"crossref","first-page":"12285","DOI":"10.1002\/cam4.5926","article-title":"Dynamics of disease progression during treatment with osimertinib in patients with EGFR T790M-positive non-small cell lung cancer","volume":"12","author":"Kim","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.annonc.2025.01.001_bib17","article-title":"Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study","volume":"4","author":"Peled","year":"2021","journal-title":"Neurooncol Adv"},{"key":"10.1016\/j.annonc.2025.01.001_bib18","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3390\/cancers15030841","article-title":"Osimertinib resistance: molecular mechanisms and emerging treatment options","volume":"15","author":"Gomatou","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.annonc.2025.01.001_bib19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2025.01.001_bib20","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1200\/JCO.23.01476","article-title":"HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor-mutated non-small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy","volume":"41","author":"Yu","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2025.01.001_bib21","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.9016","article-title":"Telisotuzumab vedotin (Teliso-V) monotherapy in patients (pts) with previously treated c-Met\u2013overexpressing (OE) advanced non-small cell lung cancer (NSCLC)","volume":"40","author":"Camidge","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2025.01.001_bib22","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.7150\/thno.38729","article-title":"Targeting microtubules sensitizes drug resistant lung cancer cells to lysosomal pathway inhibitors","volume":"10","author":"Chin","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.annonc.2025.01.001_bib23","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a009035","article-title":"Effects of membrane trafficking on signaling by receptor tyrosine kinases","volume":"5","author":"Miaczynska","year":"2013","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.annonc.2025.01.001_bib24","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s43440-020-00109-y","article-title":"Chemotherapy-induced peripheral neuropathy: part 1-current state of knowledge and perspectives for pharmacotherapy","volume":"72","author":"Sa\u0142at","year":"2020","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.annonc.2025.01.001_bib25","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in\u00a0EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2025.01.001_bib26","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S1470-2045(22)00382-5","volume":"23","author":"Lu","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2025.01.001_bib27","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/jjco\/hyad052","article-title":"Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance","volume":"53","author":"Araki","year":"2023","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.annonc.2025.01.001_bib28","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1158\/2159-8290.CD-22-0586","article-title":"Osimertinib\u00a0+ savolitinib to overcome acquired MET-mediated resistance in epidermal growth factor receptor-mutated, MET-amplified non-small cell lung cancer: TATTON","volume":"13","author":"Hartmaier","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2025.01.001_bib29","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1158\/1078-0432.CCR-16-1568","article-title":"ABBV-399, a c-Met antibody-drug conjugate that targets both MET-amplified and c-Met-overexpressing tumors, irrespective of MET pathway dependence","volume":"23","author":"Wang","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"18","key":"10.1016\/j.annonc.2025.01.001_bib30","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.3390\/cancers15184552","article-title":"Targeting MET amplification: opportunities and obstacles in therapeutic approaches","volume":"15","author":"Kumaki","year":"2023","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.annonc.2025.01.001_bib31","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.cllc.2023.06.008","article-title":"MET exon 14 skipping in NSCLC: a systematic literature review of epidemiology, clinical characteristics, and outcomes","volume":"24","author":"Mazieres","year":"2023","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.annonc.2025.01.001_bib32","article-title":"Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer","volume":"6","author":"Coleman","year":"2021","journal-title":"EMSO Open"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425000055?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425000055?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T07:32:44Z","timestamp":1777361564000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753425000055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0923753425000055"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2025.01.001","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced\/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2025.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}